Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia

Alfonso Quintás-Cardama, Jorge E. Cortés, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

The tyrosine kinase inhibitor (TKI) imatinib constitutes the current first-line therapeutic approach for patients with chronic myeloid leukemia. The success of imatinib relies on its potent inhibitory activity against the Bcr-Abl kinase that drives the pathogenesis of this disorder. The vast majority of patients treated with imatinib as a single agent will achieve a complete cytogenetic response. However, a subset of patients will develop imatinib resistance, frequently associated with mutations within the Abl kinase domain. In this setting, treatment with the second-generation TKIs nilotinib and dasatinib has proved highly efficacious. While therapy with these Bcr-Abl TKIs is generally well tolerated, adverse events are common and can result in treatment interruptions that compromise clinical responses. Herein, we discuss some of the toxicities characteristically associated with TKI therapy and provide practical approaches to the clinical management of these adverse effects.

Original languageEnglish (US)
Pages (from-to)S82-S88
JournalClinical Lymphoma and Myeloma
Volume8
Issue numberSUPPL. 3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Phosphotransferases
Therapeutics
Cytogenetics
Mutation
Imatinib Mesylate

Keywords

  • Bcr-Abl
  • Dasatinib
  • Imatinib
  • Myelosuppression
  • Nilotinib
  • Peripheral edema
  • Pleural effusion

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. / Quintás-Cardama, Alfonso; Cortés, Jorge E.; Kantarjian, Hagop.

In: Clinical Lymphoma and Myeloma, Vol. 8, No. SUPPL. 3, 03.2008, p. S82-S88.

Research output: Contribution to journalArticle

@article{c30e23f2c7c24374b8a8ccc8dff19645,
title = "Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia",
abstract = "The tyrosine kinase inhibitor (TKI) imatinib constitutes the current first-line therapeutic approach for patients with chronic myeloid leukemia. The success of imatinib relies on its potent inhibitory activity against the Bcr-Abl kinase that drives the pathogenesis of this disorder. The vast majority of patients treated with imatinib as a single agent will achieve a complete cytogenetic response. However, a subset of patients will develop imatinib resistance, frequently associated with mutations within the Abl kinase domain. In this setting, treatment with the second-generation TKIs nilotinib and dasatinib has proved highly efficacious. While therapy with these Bcr-Abl TKIs is generally well tolerated, adverse events are common and can result in treatment interruptions that compromise clinical responses. Herein, we discuss some of the toxicities characteristically associated with TKI therapy and provide practical approaches to the clinical management of these adverse effects.",
keywords = "Bcr-Abl, Dasatinib, Imatinib, Myelosuppression, Nilotinib, Peripheral edema, Pleural effusion",
author = "Alfonso Quint{\'a}s-Cardama and Cort{\'e}s, {Jorge E.} and Hagop Kantarjian",
year = "2008",
month = "3",
doi = "10.3816/CLM.2008.s.003",
language = "English (US)",
volume = "8",
pages = "S82--S88",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia

AU - Quintás-Cardama, Alfonso

AU - Cortés, Jorge E.

AU - Kantarjian, Hagop

PY - 2008/3

Y1 - 2008/3

N2 - The tyrosine kinase inhibitor (TKI) imatinib constitutes the current first-line therapeutic approach for patients with chronic myeloid leukemia. The success of imatinib relies on its potent inhibitory activity against the Bcr-Abl kinase that drives the pathogenesis of this disorder. The vast majority of patients treated with imatinib as a single agent will achieve a complete cytogenetic response. However, a subset of patients will develop imatinib resistance, frequently associated with mutations within the Abl kinase domain. In this setting, treatment with the second-generation TKIs nilotinib and dasatinib has proved highly efficacious. While therapy with these Bcr-Abl TKIs is generally well tolerated, adverse events are common and can result in treatment interruptions that compromise clinical responses. Herein, we discuss some of the toxicities characteristically associated with TKI therapy and provide practical approaches to the clinical management of these adverse effects.

AB - The tyrosine kinase inhibitor (TKI) imatinib constitutes the current first-line therapeutic approach for patients with chronic myeloid leukemia. The success of imatinib relies on its potent inhibitory activity against the Bcr-Abl kinase that drives the pathogenesis of this disorder. The vast majority of patients treated with imatinib as a single agent will achieve a complete cytogenetic response. However, a subset of patients will develop imatinib resistance, frequently associated with mutations within the Abl kinase domain. In this setting, treatment with the second-generation TKIs nilotinib and dasatinib has proved highly efficacious. While therapy with these Bcr-Abl TKIs is generally well tolerated, adverse events are common and can result in treatment interruptions that compromise clinical responses. Herein, we discuss some of the toxicities characteristically associated with TKI therapy and provide practical approaches to the clinical management of these adverse effects.

KW - Bcr-Abl

KW - Dasatinib

KW - Imatinib

KW - Myelosuppression

KW - Nilotinib

KW - Peripheral edema

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=43749083078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749083078&partnerID=8YFLogxK

U2 - 10.3816/CLM.2008.s.003

DO - 10.3816/CLM.2008.s.003

M3 - Article

C2 - 19254885

AN - SCOPUS:43749083078

VL - 8

SP - S82-S88

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - SUPPL. 3

ER -